Korea Q3 Roundup: Record Quarter For Hanmi, Daewoong, Boryung
US Approval For Hanmi’s Rolvedon
Aside from what was generally a strong quarter for South Korean biopharma firms, Hanmi faces mixed news for its US pipeline, Daewoong’s Fexuclue and Nabota expand their market presence, Boryung builds its oncology business and SK Bioscience unveils an updated growth strategy.
